HBIO
Harvard Bioscience, Inc.NASDAQHealthcare$5.53+6.35%ClosedMarket Cap: $24.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.79
P/S
0.29
EV/EBITDA
11.36
DCF Value
$1.20
FCF Yield
20.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.0%
Operating Margin
-55.9%
Net Margin
-65.5%
ROE
-388.6%
ROA
-70.8%
ROIC
-80.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $23.7M | 47.6% | $1.9M | $-2.8M | $-0.64 | — |
| FY 2025 | $86.5M | 53.0% | $-629.0K | $-56.7M | $-12.80 | — |
| Q3 2025 | $20.6M | 58.4% | $197.0K | $-1.2M | $-0.28 | — |
| Q2 2025 | $20.4M | 50.7% | $-819.0K | $-2.3M | $-0.52 | — |
| Q1 2025 | $21.8M | 56.0% | $-49.7M | $-50.3M | $-11.40 | — |
| Q4 2024 | $24.6M | 57.1% | $11.0K | $18.0K | $0.00 | — |
| FY 2024 | $94.1M | 58.2% | $-6.2M | $-12.4M | $-2.80 | — |
| Q3 2024 | $22.0M | 58.1% | $-1.9M | $-4.8M | $-1.10 | — |
| Q2 2024 | $23.1M | 57.2% | $-2.1M | $-2.9M | $-0.67 | — |
| Q1 2024 | $24.5M | 60.3% | $-2.3M | $-4.7M | $-1.10 | — |
| Q4 2023 | $28.2M | 53.1% | $282.0K | $-1.8M | $-0.43 | — |
| FY 2023 | $112.3M | 58.9% | $1.9M | $-3.4M | $-0.81 | — |